Navigation Links
BioMS Medical Announces 2007 Year End Results
Date:3/18/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, March 18 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis ("MS"), today announced financial and operational results for the year ended December 31, 2007.

"We continue to focus on the worldwide development of MBP8298, our proprietary synthetic peptide drug for the treatment of multiple sclerosis, which is being evaluated in several late-stage trials in the U.S., Canada and across Europe," said Kevin Giese, President and CEO of BioMS Medical. "The magnitude of the partnership we formed with Lilly at the end of 2007 for the global rights to MBP8298 underscores the enormous potential of our drug and is a validation of all the years of hard work performed by our team."

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for MBP8298:

- MAESTRO-01: A pivotal phase II/III trial in Canada and Western Europe

evaluating MBP8298 for the treatment of secondary progressive MS

("SPMS"). On January 22, 2007, BioMS announced that the trial had

completed full recruitment of 611 patients at 47 trial sites in

10 countries. Patients are administered either MBP8298 or placebo

every six months for a period of two years. To date, there have been

eight positive safety reviews from the Data Safety Monitoring Board

("DSMB"). An interim analysis on the first 200 patients is expected

in mid-2008.

- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal

trial. Eligible patients who have successfully completed the blinded,

placebo controlled MAESTRO-01 trial may choose to receive MBP8298 on

an un-blinded basis.

- MAESTRO-03: A U.S. pivotal phase III trial evaluating MBP8298 for the

treatment of SPMS. Enrollment for the randomized, double-blind s
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
3. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at BioContact 2007
9. BioMS Medical announces its intention to renew a normal course issuer bid
10. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
11. GHI Medical Deploys New Test to Help Determine Hair Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ...
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 Earlier ... James L. Sherley, director of the Adult Stem Cell Technology ... overlooked and under appreciated unique property of adult tissue stem ... Misunderstood in the Past, Important for the Future,” embodied the ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... law H.R. 83, the Omnibus and Continuing Resolution Appropriations ... hydrocephalus a condition eligible to receive funding through the ... Department of Defense (DoD). The Hydrocephalus Association (HA), working ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... CLEVELAND, June 22, 2011 Clinical Research Management, ... in basic and applied research, clinical trials, and ... a new, 5-year, $97MM research support contract titled ... (SMMRS) to be performed at the Walter Reed ...
... June 22, 2011 ,   ... a novel platform technology for the oral delivery of ... Berelowitz, M.D., has been appointed the Chairman of its,Scientific ... Board of Directors in May 2010,and will now expand ...
... Biodesign, a drug discovery company that utilizes ultra-high throughput ... therapeutic agents against its novel disease-based targets, or its ... medicinal chemistry space at 8 Black Forest Road in ... 11,000 square feet of state-of-the-art research laboratories and office ...
Cached Biology Technology:ClinicalRM (formerly CRM) Awarded $97MM U.S. Army Contract to Support Military Clinical Research for the Warfighter 2Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board 2Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board 3VENENUM Biodesign Announces Opening of Medicinal Chemistry Labs 2
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced today its ... confirm its adherence to current U.S. Food and Drug ... regulated smart device and smart phone application trials utilizing ... "HITLAB is determined to improve global healthcare ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... to their offering. One major trend ... continuous advances in technology, it is important to upgrade ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... to accurately measure the levels of important chemicals in ... level of a single cell. Scientists at the Carnegie ... the first to overcome this obstacle by successfully applying ... brain chemical levels. The sensors alter their 3-dimensional form ...
... A research team based at Massachusetts General Hospital (MGH) ... of RNA interference (RNAi), a powerful new research tool ... the RNAi process itself to find new genes that ... to fight human disease. The report will appear in ...
... Montreal is pleased to announce the first successful birth in ... Seang Lin Tan, Chair of the Department of Obstetrics and ... Centre at the MUHC in Montreal confirmed the birth of ... are the first in-vitro fertilization (IVF) Centre in Canada to ...
Cached Biology News:Revolutionary nanotechnology illuminates brain cells at work 2Revolutionary nanotechnology illuminates brain cells at work 3Scientists identify genetic pathways essential to RNA interference 2Scientists identify genetic pathways essential to RNA interference 3First frozen egg baby born in Canada 2First frozen egg baby born in Canada 3
... solution, Type I is ... and agarose gel electrophoresis ... offers the advantage of ... blue and xylene cyanole). ...
Rabbit polyclonal to QKI...
... SilverSNAP Stain for Mass Spectrometry Applications ... spectrometry (MS) has emerged as a powerful ... of 2-D gels is now an important ... that leads ultimately to identification of specific ...
... without ammonium sulfate are compatible with thermostable ... Taq and AmpliThem™™ DNA polymerases. You can ... in one experiment by adding your own ... PreMixes supplied with the kit. This capability ...
Biology Products: